VG Life Sciences Competitors

Novelion Therapeutics (OTCMKTS:NVLNF) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Novelion Therapeutics and VG Life Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Novelion Therapeutics and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

VG Life Sciences has lower revenue, but higher earnings than Novelion Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and price targets for Novelion Therapeutics and VG Life Sciences, as reported by MarketBeat.com.

Insider & Institutional Ownership

48.6% of Novelion Therapeutics shares are held by institutional investors. 3.6% of Novelion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Novelion Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Summary

Novelion Therapeutics beats VG Life Sciences on 4 of the 4 factors compared between the two stocks.

Intec Pharma (NASDAQ:NTEC) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Intec Pharma and VG Life Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Intec Pharma and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of current ratings and price targets for Intec Pharma and VG Life Sciences, as reported by MarketBeat.com.

Intec Pharma presently has a consensus target price of $13.00, indicating a potential upside of 239.43%. Given Intec Pharma's higher probable upside, analysts clearly believe Intec Pharma is more favorable than VG Life Sciences.

Nuvo Pharmaceuticals (OTCMKTS:NRIFF) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Nuvo Pharmaceuticals and VG Life Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Nuvo Pharmaceuticals and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Nuvo Pharmaceuticals has higher revenue and earnings than VG Life Sciences.

Analyst Ratings

This is a breakdown of current ratings and price targets for Nuvo Pharmaceuticals and VG Life Sciences, as reported by MarketBeat.com.

Risk & Volatility

Nuvo Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Summary

Nuvo Pharmaceuticals beats VG Life Sciences on 3 of the 5 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Medicure and VG Life Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Medicure and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

VG Life Sciences has lower revenue, but higher earnings than Medicure.

Risk & Volatility

Medicure has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Medicure and VG Life Sciences, as reported by MarketBeat.com.

Summary

VG Life Sciences beats Medicure on 4 of the 5 factors compared between the two stocks.

CannaPharmaRX (OTCMKTS:CPMD) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares CannaPharmaRX and VG Life Sciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares CannaPharmaRX and VG Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Risk and Volatility

CannaPharmaRX has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CannaPharmaRX and VG Life Sciences, as reported by MarketBeat.

Summary

VG Life Sciences beats CannaPharmaRX on 2 of the 3 factors compared between the two stocks.

CannaPharmaRX (OTCMKTS:CPMD) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares CannaPharmaRX and VG Life Sciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares CannaPharmaRX and VG Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Risk and Volatility

CannaPharmaRX has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CannaPharmaRX and VG Life Sciences, as reported by MarketBeat.

Summary

VG Life Sciences beats CannaPharmaRX on 2 of the 3 factors compared between the two stocks.